drugset / Trial / NCT04729062

C3G/Primary IC-MPGN EAP

NCT04729062

Expanded access Approved for marketing Apellis Pharmaceuticals, Inc.

Summary

This is an Early Access Program (EAP) which will provide access to pegcetacoplan for eligible participants with C3G and Primary IC-MPGN.

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Pegcetacoplan Peptide